No Data
No Data
No Data
No Data
No Data
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...
PR Newswire12:15 ET
Bio-Rad Laboratories(BIO.US) 10% Shareholder Sells US$148.44K in Common Stock
$Bio-Rad Laboratories(BIO.US)$ 10% Shareholder SCHWARTZ STEVEN D sold 320 shares of common stock on May 3, 2023 at an average price of $463.86 for a total value of $148.44K.Source: Announcement What i
moomoo NewsMay 1 12:33 ET
Seven Corporate Buyers Enter Into Aggregation Deal To Purchase 180 MW of Solar Energy Through the Net Zero Consortium for Buyers
BOSTON, May 1, 2024 /PRNewswire/ -- Through Sustainability Roundtable, Inc.'s Net Zero Consortium for Buyers (NZCB), Cisco, Juniper Networks, Bio-Rad Laboratories, Cadence Design Systems, IDEXX Labor
PR NewswireMay 1 09:30 ET
Bio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju
BusinesswireMay 1 09:00 ET
Bio-Rad Laboratories (BIO) Receives a Buy From RBC Capital
TipRanksApr 30 21:49 ET
RBC Capital Adjusts Price Target on Bio-Rad Laboratories to $420 From $474
Bio-Rad Laboratories (BIO) has an average buy rating and price target range of $365 to $441, according to analysts polled by Capital IQ. Price: 279.25, Change: +3.31, Percent Change: +1.20
MT NewswiresApr 29 09:40 ET
Filthy Sinatra : nice job
Mafiosa818 : top gap up and down
No Data
No Data